Emerging clinical data indicates about 3% of patients with prostate cancer have a high tumor mutation burden (microsatellite instability-high or mismatch repair deficit) and they are responsive to anti-PD-1/PD-L1 agents, with 45% (5 of 11 patients) experiencing durable clinical benefit [21]. This evidence concerns the gene CD274 and prostate carcinoma.